Security
ELAB · PMGC Holdings Inc.
ELABNASDAQCommon stockCurrentCIK 1840563Updated Sep 27, 2026
Name history
Elevai Labs Inc. · through Nov 27, 2024Reactive Medical Labs Inc. · through Oct 14, 2021
ELAB price & chart
Loading TradingView…
NASDAQ:ELAB on TradingView ↗About the company
We are dedicated to enhancing our portfolio through the acquisition of operating companies and innovative biotechnology assets that align with our growth mission, while actively pursuing the acquisition of operating companies.
In the news
These Companies Just Dropped Major Growth Catalysts ↗
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Entry into a Material Definitive Agreement · Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure
Items 1.01, 3.03, 5.03, 7.01, 9.01
Entry into a Material Definitive Agreement · Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure · Other Events
Items 1.01, 3.03, 5.03, 7.01, 8.01, 9.01
10-Q filing
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Show 5 more recent filings
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
Items 5.03, 5.07, 9.01
Entry into a Material Definitive Agreement
Items 1.01, 9.01
4 filing
Financials
FY 2025 · USDSource
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 12,868,473Source | 8,993,165Source | 5,189,918Source | 1,892,183Source |
| Property, Plant and Equipment, NetUSD | 885,520Source | 1,087Source | 53,119Source | 53,535Source |
| GoodwillUSD | 977,774Source | — | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 2,892,397Source | 2,801,993Source | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | 3,984,453Source | — | — |
| Inventory, NetUSD | 95,098Source | — | 495,667Source | 230,145Source |
| Assets, CurrentUSD | 6,871,255Source | 6,051,001Source | 4,919,444Source | 1,551,322Source |
| Prepaid Expense and Other Assets, CurrentUSD | 461,239Source | 868,464Source | 1,060,765Source | 153,422Source |
| Operating Lease, Right-of-Use AssetUSD | 1,241,527Source | — | 206,582Source | 276,553Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 5,031,111Source | 2,333,601Source | 1,362,842Source | 760,873Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 8Source | 44Source | 1,733Source | 957Source |
| Additional Paid in CapitalUSD | 28,856,496Source | — | 10,849,031Source | 3,852,044Source |
| Retained Earnings (Accumulated Deficit)USD | -21,017,440Source | -13,269,627Source | -7,023,890Source | -2,722,373Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -2,339Source | -337Source | 202Source | 111Source |
| Stockholders' Equity Attributable to ParentUSD | 7,837,362Source | 6,659,564Source | 3,827,076Source | 1,131,310Source |
| Additional Paid in Capital, Common StockUSD | — | 19,929,484Source | — | — |
| Liabilities and EquityUSD | 12,868,473Source | 8,993,165Source | 5,189,918Source | 1,892,183Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 3,942,296Source | 1,799,134Source | 1,297,353Source | 588,272Source |
| Operating Lease, Liability, CurrentUSD | 247,627Source | — | 145,000Source | 110,616Source |
| Operating Lease, Liability, NoncurrentUSD | 972,843Source | — | 65,489Source | 172,601Source |
| Deferred Income Tax Liabilities, NetUSD | 30,972Source | — | — | — |
| Additional Financial Items | ||||
| Deferred Tax Liabilities, NetUSD | 30,972Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | -19,160Source | 97,167Source | 487,738Source | 171,869Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | 23,218Source | 11,547Source |
| Increase (Decrease) in InventoriesUSD | -147,868Source | 403,295Source | 265,522Source | 69,328Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | 466,891Source | 65,191Source |
| Deferred Income Tax Expense (Benefit)USD | 30,972Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -5,933,881Source | -5,486,980Source | -4,556,811Source | -1,585,876Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 2,162,756Source | — | — | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -2,765,154Source | -610,564Source | -11,191Source | -32,027Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 442,255Source | 9,160Source | — | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 10,116,738Source | 6,757,500Source | 6,738,890Source | 2,362,259Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 1,417,880Source | 657,602Source | 2,171,950Source | 743,043Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 5,402,333Source | 3,984,453Source | 3,326,851Source | 1,154,901Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 37,770Source | 69,026Source | 14,397Source | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 177Source | -2,354Source | 1,062Source | -1,313Source |
| Additional Financial Items | ||||
| Accretion ExpenseUSD | 130,766Source | — | — | — |
| Share-based Payment Arrangement, ExpenseUSD | -19,160Source | 97,167Source | 135,947Source | 47,906Source |
| Amortization of Intangible AssetsUSD | 14,568Source | — | — | — |
| DepreciationUSD | 96,663Source | 12,950Source | 11,649Source | 6,512Source |
| Depreciation, NonproductionUSD | — | 546Source | 10,295Source | 5,034Source |
| Financing Interest ExpenseUSD | 289,498Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -5,238Source | -5,846Source | -6,130Source | -2,749Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | 129,613Source | — | — | — |
| Gain (Loss) on InvestmentsUSD | 728,550Source | — | — | — |
| Gain (Loss) on Sale of InvestmentsUSD | -113,917Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -32,432Source | — | — | -1,546Source |
| Gain (Loss) on Extinguishment of DebtUSD | 31,261Source | — | — | — |
| General and Administrative ExpenseUSD | 2,238,660Source | 1,092,576Source | 2,329,067Source | 1,019,708Source |
| GoodwillUSD | 977,774Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -7,780,740Source | -4,016,714Source | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | 32,927Source | -2,229,023Source | — | — |
| Income Tax Expense (Benefit)USD | 30,972Source | — | — | — |
| InterestExpenseNonoperatingUSD | 257,630Source | 735,197Source | — | — |
| Investment Income, InterestUSD | 118,030Source | 12,891Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -7,747,813Source | -6,245,737Source | -4,301,517Source | -1,800,268Source |
| Nonoperating Income (Expense)USD | — | — | -3,766,211Source | -1,791,041Source |
| Operating ExpensesUSD | 7,067,262Source | 3,663,566Source | 4,900,791Source | 2,238,350Source |
| Other Nonoperating Income (Expense)USD | — | — | -535,306Source | — |
| Other Operating Income (Expense), NetUSD | — | 11,937,946Source | 4,168,622Source | 1,615,645Source |
| Payments for Repurchase of WarrantsUSD | 179Source | — | — | — |
| Payments to Acquire InvestmentsUSD | 1,789,044Source | 139,084Source | — | — |
| Proceeds from Contributed CapitalUSD | — | — | 158,603Source | — |
| Proceeds from Issuance of Common StockUSD | — | 6,993,058Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | 37,500Source | 25,000Source |
| Realized Investment Gains (Losses)USD | -113,917Source | — | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 590,084Source | — | — | — |
| Unrealized Gain (Loss) on DerivativesUSD | — | — | -91,009Source | -74,003Source |
| Unrealized Gain (Loss) on InvestmentsUSD | -216,043Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 590,084Source | — | 1,712,595Source | 766,277Source |
| Cost of RevenueUSD | 404,770Source | — | 578,015Source | 318,968Source |
| Other Nonoperating Income (Expense)USD | — | — | -535,306Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -7,749,768Source | — | — | — |
| Income Tax Expense (Benefit)USD | 30,972Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -7,747,813Source | -6,245,737Source | -4,301,517Source | -1,800,268Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.4Source | -0.19Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.4Source | -0.19Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 20,352Source | 79,582Source | 10,745,938Source | 9,528,863Source |
| Interest Expense (non-operating)USD | 257,630Source | 735,197Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 14,568Source | — | — | — |
| Costs and ExpensesUSD | — | — | 4,900,791Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 96,145Source | — | — | — |
| Financing Interest ExpenseUSD | 289,498Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -5,238Source | -5,846Source | -6,130Source | -2,749Source |
| Gain (Loss) on InvestmentsUSD | 728,550Source | — | — | — |
| General and Administrative ExpenseUSD | 2,238,660Source | 1,092,576Source | 2,329,067Source | 1,019,708Source |
| Gross ProfitUSD | 185,314Source | — | 1,134,580Source | 447,309Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -7,780,740Source | -4,016,714Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 8,353,923Source | — | — | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -382.3Source | -50.47Source | — | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -382.3Source | -50.47Source | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | 32,927Source | -2,229,023Source | — | — |
| Interest ExpenseUSD | — | — | 19,525Source | 2,629Source |
| Interest Expense, DebtUSD | 103,294Source | — | — | — |
| Interest Income, OtherUSD | — | — | 5,564Source | 7,702Source |
| Investment Income, InterestUSD | 118,030Source | 12,891Source | — | — |
| Management Fee ExpenseUSD | 1,769,505Source | 1,367,273Source | 459,498Source | 324,395Source |
| Marketing and Advertising ExpenseUSD | 200,940Source | 292,522Source | 124,376Source | 36,501Source |
| Net Income (Loss) Attributable to Nonredeemable Noncontrolling InterestUSD | — | — | 4,301,517Source | — |
| Nonoperating Income (Expense)USD | — | — | -3,766,211Source | -1,791,041Source |
| Operating ExpensesUSD | 7,067,262Source | 3,663,566Source | 4,900,791Source | 2,238,350Source |
| Other Operating Income (Expense), NetUSD | — | 11,937,946Source | 4,168,622Source | 1,615,645Source |
| Realized Investment Gains (Losses)USD | -113,917Source | — | — | — |
| Research and Development ExpenseUSD | 147,010Source | 104,654Source | 426,243Source | 228,747Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 590,084Source | — | — | — |
| Selling and Marketing ExpenseUSD | — | — | 660,291Source | 192,863Source |
Offerings
Registration 333-290428
Registration 333-290902
Registration 333-284851
Filing attachments
ea030585501ex99-1.htm · 8-K · 2026-09-18
EX-99.1 2 ea030585501ex99-1.htm PRESS RELEASE DATED SEPTEMBER 18, 2026 Exhibit 99.1 PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdings Binding, interest-bearing payment plan converts PMGC’s 5% net sales royalty into scheduled monthly cash payments to NorthStrive Biosciences through August 2031, creating recurring, non-dilutive cash flow. ───────────────────────────────────────────…
Read attachment ↗ea030441901ex99-1.htm · 8-K · 2026-09-02
EX-99.1 4 ea030441901ex99-1.htm PRESS RELEASE DATED SEPTEMBER 1, 2026 Exhibit 99.1 NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four AI-Discovered Compounds Toward Lead Nomination in Cardiac Disease and Obesity Pursuant to a First Amendment to the Development and License Agreement, NorthStrive Biosciences and Yuva Biosciences launch a three-phase Expansion Program to advance all four AI-discovered compounds toward lead compound nominatio…
Read attachment ↗ea030362001ex99-1.htm · 8-K · 2026-08-27
EX-99.1 5 ea030362001ex99-1.htm PRESS RELEASE DATED AUGUST 25, 2026 Exhibit 99.1 PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss Proposed Mice2Space spaceflight study would evaluate EL-22 and EL-32 in mice in a real-world microgravity environment, targeting one of the most significant physiological challenges of spaceflight Three-…
Read attachment ↗ea030362001ex99-2.htm · 8-K · 2026-08-27
EX-99.2 6 ea030362001ex99-2.htm PRESS RELEASE DATED AUGUST 26, 2026 Exhibit 99.2 PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio Company prioritizes disciplined capital allocation while expanding machining capacity, integrating portfolio operations and evaluating robotics and automation to support organic growth NEWPORT BEACH, Calif., A…
Read attachment ↗ea029652701ex99-1.htm · 8-K · 2026-07-01
EX-99.1 2 ea029652701ex99-1.htm PRESS RELEASE DATED JULY 1, 2026 Exhibit 99.1 NorthStrive Biosciences Announces Positive Results from Phase III of AI-Driven Drug Discovery Program with Yuva Biosciences Yuva Biosciences' proprietary MitoNova™ AI platform identified small-molecule candidates that were biologically validated in primary human skeletal muscle cells, with multiple candidates increasing ANT1, a mitochondrial protein central to skeletal muscle energy metabolism. Four AI-s…
Read attachment ↗ea029009801ex99-1.htm · 8-K · 2026-05-13
EX-99.1 3 ea029009801ex99-1.htm UNAUDITED FINANCIAL STATEMENTS OF A&B AEROSPACE, INC. AS OF THE NINE MONTHS ENDED FEBRUARY 28, 2026 AND FEBRUARY 28, 2025 Exhibit 99.1 Financial Statements of A&B AEROSPACE, INC. For the three and nine months ended February 28, 2026 and 2025 (Unaudited) A&B AEROSPACE, INC. Balance Sheet (unaudited) As of: Note Feb 28, May 31, …
Read attachment ↗